Identification of Microbial Species and Analysis of Antimicrobial Resistance Patterns in Acute Cholangitis Patients with Malignant and Benign Biliary Obstructions: A Comparative Study

Background and Objectives: Acute cholangitis (AC) is still lethal if not treated promptly and effectively. Biliary drainage, also known as source control, has been acknowledged as the backbone treatment for patients with AC; nonetheless, antimicrobial therapy allows these patients to undergo non-emergent drainage procedures. This retrospective study aims to observe the bacterial species involved in AC and analyze the antimicrobial resistance patterns. Materials and Methods: Data were collected for four years, comparing patients with benign and malignant bile duct obstruction as an etiology for AC. A total of 262 patients were included in the study, with 124 cases of malignant obstruction and 138 cases of benign obstruction. Results: Positive bile culture was obtained in 192 (73.3%) patients with AC, with a higher rate among the benign group compared with malignant etiologies (55.7%.vs 44.3%). There was no significant difference between the Tokyo severity scores in the two study groups, identifying 34.7% cases of malignant obstruction with Tokyo Grade 1 (TG1) and 43.5% cases of TG1 among patients with benign obstruction. Similarly, there were no significant differences between the number of bacteria types identified in bile, most of them being monobacterial infections (19% in the TG1 group, 17% in the TG2 group, and 10% in the TG3 group). The most commonly identified microorganism in blood and bile cultures among both study groups was E. coli (46.7%), followed by Klebsiella spp. (36.0%) and Pseudomonas spp. (8.0%). Regarding antimicrobial resistance, it was observed that significantly more patients with malignant bile duct obstruction had a higher percentage of bacterial resistance for cefepime (33.3% vs. 11.7%, p-value = 0.0003), ceftazidime (36.5% vs. 14.5%, p-value = 0.0006), meropenem (15.4% vs. 3.6%, p-value = 0.0047), and imipenem (20.2% vs. 2.6%, p-value < 0.0001). Conclusions: The positive rate of biliary cultures is higher among patients with benign biliary obstruction, while the malignant etiology correlates with increased resistance to cefepime, ceftazidime, meropenem, and imipenem.

[1]  Ming-Hui Sun,et al.  Infection Sources and Klebsiella pneumoniae Antibiotic Susceptibilities in Endogenous Klebsiella Endophthalmitis , 2022, Antibiotics.

[2]  Jitao Song,et al.  A Retrospective Study on Bile Culture and Antibiotic Susceptibility Patterns of Patients with Biliary Tract Infections , 2022, Evidence-based complementary and alternative medicine : eCAM.

[3]  B. Bick,et al.  Microbiology of bile aspirates obtained at ERCP in patients with suspected acute cholangitis , 2022, Endoscopy.

[4]  P. Fockens,et al.  Performance of diagnostic tools for acute cholangitis in patients with suspected biliary obstruction , 2021, Journal of hepato-biliary-pancreatic sciences.

[5]  Takayuki Otani,et al.  Blood cultures should be collected for acute cholangitis regardless of severity. , 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[6]  Bian Wu,et al.  Fatal Infections Among Cancer Patients: A Population-Based Study in the United States , 2021, Infectious Diseases and Therapy.

[7]  A. S. Attia,et al.  Molecular Characterization of Carbapenemase-Producing Klebsiella pneumoniae Isolated from Egyptian Pediatric Cancer Patients Including a Strain with a Rare Gene-Combination of β-Lactamases , 2021, Infection and drug resistance.

[8]  E. D. Di Domenico,et al.  Biofilm Production by Carbapenem-Resistant Klebsiella pneumoniae Significantly Increases the Risk of Death in Oncological Patients , 2020, Frontiers in Cellular and Infection Microbiology.

[9]  F. Vleggaar,et al.  Urgent endoscopic retrograde cholangiopancreatography with sphincterotomy versus conservative treatment in predicted severe acute gallstone pancreatitis (APEC): a multicentre randomised controlled trial , 2020, The Lancet.

[10]  P. Fockens,et al.  Antimicrobial therapy of 3 days or less is sufficient after successful ERCP for acute cholangitis , 2020, United European gastroenterology journal.

[11]  A. Siddiqui,et al.  Timing of Performing Endoscopic Retrograde Cholangiopancreatography and Inpatient Mortality in Acute Cholangitis: A Systematic Review and Meta-Analysis , 2020, Clinical and translational gastroenterology.

[12]  M. S. Hakim,et al.  Biofilm formation and antibiotic resistance of Klebsiella pneumoniae isolated from clinical samples in a tertiary care hospital, Klaten, Indonesia , 2019, BMC Proceedings.

[13]  G. Duan,et al.  The resistance mechanism of Escherichia coli induced by ampicillin in laboratory , 2019, Infection and drug resistance.

[14]  A. Sauvanet,et al.  Acute cholangitis: Diagnosis and management , 2019, Journal of Visceral Surgery.

[15]  R. Shah,et al.  Early vs late endoscopic retrograde cholangiopancreatography in patients with acute cholangitis: A nationwide analysis , 2019, World journal of gastrointestinal endoscopy.

[16]  P. Hegyi,et al.  Short-Course Antibiotic Treatment Is Not Inferior to a Long-Course One in Acute Cholangitis: A Systematic Review , 2018, Digestive Diseases and Sciences.

[17]  S. Chandra,et al.  Endoscopic Retrograde Cholangio-Pancreatography-Obtained Bile Culture Can Guide Antibiotic Therapy in Acute Cholangitis , 2018, Digestive Diseases.

[18]  P. Meyers,et al.  Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke , 2018, American Journal of Neuroradiology.

[19]  D. Gouma,et al.  Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis , 2018, Journal of hepato-biliary-pancreatic sciences.

[20]  D. Gouma,et al.  Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos) , 2018, Journal of hepato-biliary-pancreatic sciences.

[21]  D. Gouma,et al.  Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis , 2018, Journal of hepato-biliary-pancreatic sciences.

[22]  A. MacCormick,et al.  Diagnostic accuracy of Charcot's triad: a systematic review , 2017, ANZ journal of surgery.

[23]  Alan E. Jones,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 , 2017, Intensive Care Medicine.

[24]  Robert A. Weinstein,et al.  The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace , 2017, The Journal of infectious diseases.

[25]  A. Stallmach,et al.  Correction: Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis , 2017, PloS one.

[26]  K. Rolston.  Infections in Cancer Patients with Solid Tumors: A Review , 2017, Infectious Diseases and Therapy.

[27]  A. Stallmach,et al.  Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis , 2017, PloS one.

[28]  W. Stremmel,et al.  Microbiological Assessment of Bile and Corresponding Antibiotic Treatment , 2016, Medicine.

[29]  J. Aguado,et al.  Bloodstream infections in patients with solid tumors , 2016, Virulence.

[30]  D. Morgan,et al.  Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. , 2015, The Lancet. Infectious diseases.

[31]  K. Iwata,et al.  Re: TG13 antimicrobial therapy for acute cholangitis and cholecystitis , 2014, Journal of hepato-biliary-pancreatic sciences.

[32]  D. Gouma,et al.  TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos) , 2013, Journal of hepato-biliary-pancreatic sciences.

[33]  L. Rice.  Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. , 2008, The Journal of infectious diseases.

[34]  G. Rait,et al.  Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes , 2007, Postgraduate Medical Journal.

[35]  Chien-Chang Lee,et al.  Epidemiology and Prognostic Determinants of Patients with Bacteremic Cholecystitis or Cholangitis , 2007, The American Journal of Gastroenterology.

[36]  Masahiro Yoshida,et al.  Antimicrobial therapy for acute cholangitis: Tokyo Guidelines , 2007, Journal of hepato-biliary-pancreatic surgery.

[37]  Masahiro Yoshida,et al.  Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines , 2007, Journal of hepato-biliary-pancreatic surgery.

[38]  D. Gouma,et al.  Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines , 2007, Journal of hepato-biliary-pancreatic surgery.

[39]  S. Sherman,et al.  Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. , 2002, Gastrointestinal endoscopy.

[40]  E. Bouza,et al.  Klebsiella and enterobacter: antibiotic resistance and treatment implications. , 2002, Seminars in respiratory infections.

[41]  M. Bonora,et al.  Evaluation of the VITEK 2 System for Identification and Antimicrobial Susceptibility Testing of Medically Relevant Gram-Positive Cocci , 2002, Journal of Clinical Microbiology.

[42]  S. Fan,et al.  Endoscopic biliary drainage for severe acute cholangitis , 1992, The New England journal of medicine.

[43]  R. Canelo,et al.  Significance of Bile Culture and Biliary Tract Pathology in Determining Severity of Cholangitis ; Review of Current Literature , 2017 .

[44]  Cher Heng Tan,et al.  Recurrent pyogenic cholangitis: a review of imaging findings and clinical management , 2016, Abdominal Radiology.

[45]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[46]  S. E. Johnson,et al.  Acute suppurative cholangitis, a medical and surgical emergency. A review of ten years experience emphasizing early recognition. , 1970, The American journal of gastroenterology.